5 patents currently held
15 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Apr 2038. from the record
Of the 15 now held by other companies, 5 name Neutrolis Inc. as their current owner, and 10 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Apr 2038
Next term end
5
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Apr 2038 · High confidence
Also notable
Ends Jun 2040 · High confidence
Also notable
Ends Dec 2043 · High confidence
Microrna 19A/19B for Use in Treating a Pathological Condition Associated with Bone Loss or Reduced Muscle Function
US 11,793,828
Granted 2023. Computed term ends 2038.
Binding Molecule Activating FXII
US 11,846,641
Granted 2023. Computed term ends 2040.
ARTC1 Ligands for Cancer Treatment
US 12,780,942
Granted 2026. Too new for citation comparison; protection runs to 2043.
Formerly held, still cited
Notable
Ends Aug 2038 · Medium confidence
Also notable
The most cited patent in this portfolio, cited by 15 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2038.
now held by Neutrolis, Inc.
Gene-Therapy Vectors for Treating Cardiomyopathy
US 10,501,756
Cited by 14 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2034.
now held by Carrier, Lucie
Also notable
Ends May 2032 · Medium confidence
The largest patent family in this portfolio, 5 related applications, renewed at 2 of 3 maintenance windows. Protection runs to 2032.
now held by Yeda Research and Development Co. Ltd.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 24, 2027The maintenance fee for Microrna 19A/19B for Use in Treating a Pathological Condition Associated with Bone Loss or Reduced Muscle Function (US 11,793,828) comes due Apr 24, 2027. Unpaid by Oct 25, 2027, it lapses early.
- 1 fee due Jun 19, 2027The maintenance fee for Binding Molecule Activating FXII (US 11,846,641) comes due Jun 19, 2027. Unpaid by Dec 20, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| ARTC1 Ligands for Cancer Treatment | 1 in force | to Dec 2043 |
| Medical Training Model Having at Least One Blood Vessel Model | 1 in force | to Jun 2042 |
| Binding Molecule Activating FXII | 1 in force | to Jun 2040 |
| Vhh-Containing Heavy Chain Antibody and Production Thereof | 1 in force | to Feb 2040 |
| Microrna 19A/19B for Use in Treating a Pathological Condition Associated with Bone Loss or Reduced Muscle Function | 1 in force | to Apr 2038 |
Patents held now
Soonest term end first.
Showing 1 to 5 of 5
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,793,828 | Microrna 19A/19B for Use in Treating a Pathological Condition Associated with Bone Loss or Reduced Muscle Function In force · High confidence | In force | High confidence | |
| US 12,673,984 | Vhh-Containing Heavy Chain Antibody and Production Thereof In force · High confidence | In force | High confidence | |
| US 11,846,641 | Binding Molecule Activating FXII In force · High confidence | In force | High confidence | |
| US 12,431,040 | Medical Training Model Having at Least One Blood Vessel Model In force · High confidence | In force | High confidence | |
| US 12,780,942 | ARTC1 Ligands for Cancer Treatment In force · High confidence | In force | High confidence |
Also on record, not counted in the 5: 15 patents in force now held by others · 1 patent ended · 16 applications pending · 14 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.